Loading...

Biovica to host conference call to provide third quarter 2018/2019 business update

On March 21, 2018, at 08:00 am CET, Biovica International AB (publ) will publish its interim report for the third quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 09:00 am CET. The event will be hosted by Biovica’s CEO Anders Rylander and CFO Cecilia Driving. The presentation will be held in English.

2019-10-20T08:48:51+00:00 March 18th, 2019 08:00|News|

Biovica moves to Nasdaq First North Premier

Uppsala, March 4, 2019. Biotechnology company Biovica announces today that Nasdaq has approved the company’s application to move from Nasdaq First North to be listed on Nasdaq First North Premier. The transition is an important part of the ambition to be listed on the stock exchange’s main list. The trading of Biovica’s share on Nasdaq First North Premier begins on Monday the 4th of March 2019.

2019-10-20T08:48:51+00:00 March 4th, 2019 07:56|Press Release|

DiviTum provides first biomarker evidence for evaluating palbociclib efficacy in new clinical study presented at AACR

New DiviTum results from a clinical study led by Dr Luca Malorni from the Prato Hospital, Italy will be presented at the American Association of Cancer Research annual meeting, 29 March-3 April, in Atlanta. The study results show that DiviTum can evaluate palbociclib treatment responses in women with breast cancer, supporting the potential of the biomarker as a clinically valuable technology for evaluating the effects of a new, targeted breast cancer therapy.

2019-10-20T08:48:51+00:00 February 28th, 2019 07:57|News|

Lars Holmqvist nominated as chairman for Biovica

Lars Holmqvist is nominated to be elected as chairman for Biovica at an upcoming extra shareholders meeting on the 20th of March 2019. Lars will replace Göran Brorsson, who wishes to reduce his workload.

2019-10-20T08:48:51+00:00 February 22nd, 2019 08:00|News|

Biovica announces that the company’s quality system is updated in accordance with  ISO 13485:2016.

Uppsala, Sweden, February 4, 2019. Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, announced today that the company has certified their Quality System according to the ISO13485:2016 standard for the development, manufacturing and sale of DiviTum® at the yearly surveillance audit with Biovica’s notified body.  

2019-10-20T08:48:51+00:00 February 4th, 2019 07:57|News|

Biovica carries out a project at Testa Center in order to scale up production to meet expected demand

Uppsala, Sweden, January 31, 2019. The biotech company Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, takes the next step in their expansion plan. Biovica will scale up production in the newly built facilities at Testa Center in Uppsala to meet the future demand from customers.

2019-10-20T08:48:51+00:00 January 31st, 2019 09:17|News|

Biovica establishes office in Boston

Biovica opens an office in Boston, the first office in the US. Pontus Nobréus, Business Development Director, will be heading up the office and will be based in Boston from 1st of January 2019.

2019-10-20T08:48:51+00:00 December 4th, 2018 08:00|News|